Compare CVBF & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVBF | PBLS |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 2009 | 2026 |
| Metric | CVBF | PBLS |
|---|---|---|
| Price | $21.96 | $29.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $26.00 | ★ $41.75 |
| AVG Volume (30 Days) | ★ 1.1M | 679.6K |
| Earning Date | 10-21-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | $14.15 | $222.58 |
| P/E Ratio | $33.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.95 | $25.56 |
| 52 Week High | $23.41 | $42.49 |
| Indicator | CVBF | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 39.57 |
| Support Level | $19.89 | $26.42 |
| Resistance Level | $21.48 | $33.65 |
| Average True Range (ATR) | 0.38 | 3.16 |
| MACD | -0.10 | -0.72 |
| Stochastic Oscillator | 0.62 | 20.05 |
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.